Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 348

1.

Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

Bongiovanni M, Tordato F.

Curr Med Chem. 2006;13(23):2789-93. Review.

PMID:
17073629
2.

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.

Infection. 2007 Dec;35(6):451-6. Epub 2007 Nov 21.

PMID:
18034204
3.

[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].

Cervero M, Torres R, Jusdado JJ, Rodríguez-Rosado R, Del Alamo M, García-Benaya E.

Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. Spanish.

PMID:
16956530
4.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA.

AIDS. 2005 Apr 29;19(7):695-8.

PMID:
15821395
5.

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.

Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V.

AIDS. 2005 Mar 24;19(6):569-75.

PMID:
15802975
6.

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

Barreiro P, Soriano V.

J Antimicrob Chemother. 2006 May;57(5):806-9. Epub 2006 Mar 10.

7.

The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M.

HIV Med. 2005 May;6(3):151-4.

8.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
9.

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitjà E, Clotet B.

AIDS. 2004 Feb 20;18(3):459-63.

PMID:
15090798
10.

Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

Moreno S, Hernández B, Dronda F.

Drugs. 2007;67(10):1441-62. Review.

PMID:
17600392
11.

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.

Karrer U, Ledergerber B, Furrer H, Elzi L, Battegay M, Cavassini M, Gayet-Ageron A, Hirschel B, Schmid P, Russotti M, Weber R, Speck RF; Swiss HIV Cohort Study.

AIDS. 2005 Nov 18;19(17):1987-94.

PMID:
16260905
12.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
13.

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.

Int J STD AIDS. 2003 May;14(5):350-5.

PMID:
12803944
14.

[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].

Pulido F, Fiorante S.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:13-8. Review. Spanish.

PMID:
19195433
15.

[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].

Bernardino de la Serna JI, Mora Rillo M, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:7-12. Review. Spanish.

PMID:
19195432
16.

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.

León A, Mallolas J, Martinez E, De Lazzari E, Pumarola T, Larrousse M, Milincovic A, Lonca M, Blanco JL, Laguno M, Biglia A, Gatell JM.

AIDS. 2005 Oct 14;19(15):1695-7.

PMID:
16184042
17.

K65R, TAMs and tenofovir.

Miller MD.

AIDS Rev. 2004 Jan-Mar;6(1):22-33. Review.

PMID:
15168738
18.

New nucleoside/nucleotide backbone options: a review of recent studies.

Ruane PJ, DeJesus E.

J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S21-9. Review.

PMID:
15319666
19.

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

Theys K, Vercauteren J, Abecasis AB, Libin P, Deforche K, Vandamme AM, Camacho R.

Infect Genet Evol. 2009 Jul;9(4):683-8. doi: 10.1016/j.meegid.2008.10.013. Epub 2008 Nov 6.

PMID:
19038365
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk